Search | Page 6 | Aplastic Anemia and MDS International Foundation

Search

Search results

  1. Azacitidine-lenalidomide (ViLen) combination yields a high response rate in higher risk myelodysplastic syndromes (MDS)-ViLen-01 protocol

    ... with less than 50 % response, lasting 2 years. Aza and lenalidomide (Len) have a potential synergistic effect. ViLen-01 phase IIa ...

    Research Article last updated 09/13/2016 - 2:47pm.

  2. Myelodysplastic Syndromes in Adolescent Young Adults: One Institution's Experience

    ... use or response to hypomethylating agents were observed. Lenalidomide therapy was seldom used in AYA, as none presented with del5q. ...

    Research Article last updated 09/19/2016 - 11:09am.

  3. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure

    ... architectures specifically upon treatment with lenalidomide and other drugs. Despite initial clinical response to ...

    Research Article last updated 07/18/2016 - 11:18am.

  4. Clinical Utility of Lenalidomide in the Treatment of Myelodysplastic Syndromes

    ... Abstract:  Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes ... This article reviews lenalidomide in the setting of myelodysplastic syndromes (MDS). ...

    Research Review last updated 05/02/2016 - 9:12am.

  5. Recent developments in myelodysplastic syndromes

    ... approval of azacitidine , decitabine , and lenalidomide between 2004 and 2006 seemed to herald a new era in the ...

    Research Article last updated 04/29/2016 - 11:34am.

  6. Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study

    ... isolated del(5q). METHODS: Patients received lenalidomide 10 mg/day (days 1-21; n = 47) or 5 mg/day (days 1-28; ... cycles, or placebo (n = 45). From the placebo and lenalidomide 5 mg groups, 84% and 58% of patients, respectively, crossed over ...

    Research Article last updated 07/29/2014 - 12:12pm.

  7. Myelodysplastic syndromes: Contemporary review and how we treat

    ... (HMA) azacitidine and decitabine and lenalidomide for MDS with isolated del(5q). To date, allogeneic stem ...

    Research Article last updated 04/29/2016 - 1:05pm.

  8. Personalized medicine for MDS

    ... treatment for MDS.  The classic example is the use of lenalidomide for patients with a del (5q) abnormality.  -In recent ... and the average length of response is 2 years.  -Lenalidomide works best in patients with red blood cell transfusion ...

    Research Review last updated 05/02/2016 - 9:44am.

  9. Outlook and Management of Patients with Myelodysplastic Syndromes Failed by Hypomethylating Agents.

    ... supportive care alone, cytotoxic therapy, lenalidomide , histone deacetylase inhibitors, and HSCT, favorable ...

    Research Article last updated 11/19/2015 - 8:32am.

  10. Anemia as the Main Manifestation of Myelodysplastic Syndromes

    ... in hereditary anemias like Blackfan Diamond anemia. Lenalidomide is the agent that has shown striking and specific ...

    Research Article last updated 12/02/2015 - 8:45am.